The effects of probiotics supplementation timing on an ovalbumin-sensitized rat model.
The aim of the present study was to investigate the effect of oral probiotic bacteria administration at different times on ovalbumin-sensitized rats. Brown-Norway (BN) rats were orally sensitized with ovalbumin for 6 weeks. Probiotics were administered before the initial sensitization (prevention group) or at the end of sensitization period (treatment group). In whole-course intervention group, probiotics were administered 2 weeks before the initial sensitization until 1 week after the end of sensitization period. Ovalbumin-immunoglobulin E (IgE) level, intestinal barrier function and immune responses were analyzed. The positive control group had a significantly increased ovalbumin-IgE level (P<0.05), impaired intestinal barrier function and skewed T-helper 1 (Th1)/Th2 cytokine balance compared with the negative control group. In probiotics prevention and whole-course intervention groups, the infiltration of inflammatory cells (eosinophil and mast cells) in small intestinal mucosa was significantly lower (P<0.05), and the ratio of cytokine interferon-γ/interleukin-4 produced by spleen and mesenteric lymph nodes significantly higher (P<0.05) than in the positive control group, which suggested a cytokine profile inclined to Th1. Both probiotics prevention and prebiotics treatment could attenuate food allergic response. Probiotics prevention tends to modulate the immune response, whereas probiotics treatment has a more obvious effect in enhancing intestinal integrity.
Huang
Juan
J
Department of Pediatric Surgery, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhong
Yan
Y
Cai
Wei
W
Zhang
Hongbo
H
Tang
Wenjing
W
Chen
Bing
B
D000818:Animals; D058491:Bacterial Load; D001644:Bifidobacterium / Q000276:immunology / Q000502:physiology; D003106:Colon / Q000382:microbiology; D016207:Cytokines / Q000096:biosynthesis / Q000378:metabolism; D004195:Disease Models, Animal; D004804:Eosinophils / Q000276:immunology; D005260:Female; D005512:Food Hypersensitivity / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D007071:Immunoglobulin A, Secretory; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D007413:Intestinal Mucosa / Q000276:immunology / Q000382:microbiology / Q000502:physiology; D007421:Intestine, Small / Q000276:immunology / Q000473:pathology; D052201:Lacticaseibacillus rhamnosus / Q000276:immunology / Q000502:physiology; D008198:Lymph Nodes / Q000276:immunology; D008407:Mast Cells / Q000276:immunology; D010047:Ovalbumin / Q000276:immunology; D010539:Permeability; D019936:Probiotics / Q000008:administration & dosage* / Q000494:pharmacology*; D051381:Rats; D011914:Rats, Inbred BN; D058408:Th1-Th2 Balance
D016207:Cytokines; D007071:Immunoglobulin A, Secretory; D015847:Interleukin-4; D007073:Immunoglobulin E; D007371:Interferon-gamma; D010047:Ovalbumin